Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Raised by Bellecapital International Ltd.

Bellecapital International Ltd. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 44.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,600 shares of the biopharmaceutical company’s stock after purchasing an additional 6,002 shares during the quarter. Regeneron Pharmaceuticals comprises about 2.5% of Bellecapital International Ltd.’s investment portfolio, making the stock its 15th largest holding. Bellecapital International Ltd.’s holdings in Regeneron Pharmaceuticals were worth $13,962,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. Focus Financial Network Inc. grew its holdings in Regeneron Pharmaceuticals by 7.4% during the third quarter. Focus Financial Network Inc. now owns 538 shares of the biopharmaceutical company’s stock worth $566,000 after acquiring an additional 37 shares during the period. Americana Partners LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $330,000. Farther Finance Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 7.9% during the third quarter. Farther Finance Advisors LLC now owns 724 shares of the biopharmaceutical company’s stock worth $761,000 after acquiring an additional 53 shares during the period. Empire Life Investments Inc. acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $5,030,000. Finally, Van ECK Associates Corp grew its holdings in Regeneron Pharmaceuticals by 8.9% during the third quarter. Van ECK Associates Corp now owns 58,136 shares of the biopharmaceutical company’s stock worth $61,115,000 after acquiring an additional 4,742 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of Regeneron Pharmaceuticals stock opened at $698.74 on Friday. The firm has a market cap of $76.39 billion, a price-to-earnings ratio of 18.25, a P/E/G ratio of 2.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The stock has a 50-day simple moving average of $698.51 and a 200-day simple moving average of $868.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company earned $11.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on REGN shares. Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Sanford C. Bernstein lowered their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Finally, Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.